eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
2/2023
vol. 18
 
Share:
Send email
Share:
abstract:
Review paper

Effects of PCSK9 inhibitors on metabolic-associated fatty liver disease: a short review

Ewelina Jakielska
1
,
Paweł Głuszak
1
,
Marta Walczak
2
,
Wiesław Bryl
2

  1. Student Internal Medicine Research Society, Poznan University of Medical Sciences, Poznan, Poland
  2. Department of Internal Medicine, Metabolic Disorders and Hypertension, Poznan University of Medical Sciences, Poznan, Poland
Gastroenterology Rev 2023; 18 (2): 148–153
DOI: https://doi.org/10.5114/pg.2023.126054
Online publish date: 2023/03/23
View full text Get citation
 
PlumX metrics:
Metabolic-associated fatty liver disease (MAFLD), previously known as non-alcoholic fatty liver disease, is a significant epidemiological problem and a well-known cardiovascular risk factor. The increasing number of cases creates the need for new therapeutic methods aimed at improving patient outcomes. Recent studies have highlighted the relationship between MAFLD and proprotein convertase subtilisin/kexin type 9 (PCSK9). Based on the available data, PCSK9 inhibitors appear to have beneficial effects in patients with MAFLD, and they may be a treatment option in the future. Further research is necessary to better evaluate the efficiency of PCSK9 inhibitors in MAFLD treatment.
keywords:

non-alcoholic fatty liver disease, fatty liver, PCSK9
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.